Total Payments
$433,239
2024 Payments
$59,271
Companies
45
Transactions
1,106
Medicare Patients
8,363
Medicare Billing
$2.7M
Payment Breakdown by Category
Other$360,522 (83.2%)
Food & Beverage$33,549 (7.7%)
Consulting$23,406 (5.4%)
Travel$15,410 (3.6%)
Education$352.76 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $360,522 | 161 | 83.2% |
| Food and Beverage | $33,549 | 814 | 7.7% |
| Consulting Fee | $23,406 | 11 | 5.4% |
| Travel and Lodging | $15,410 | 110 | 3.6% |
| Education | $352.76 | 10 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $211,072 | 256 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $71,915 | 178 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $59,405 | 140 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $25,019 | 45 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $19,727 | 72 | $0 (2022) |
| ABBVIE INC. | $19,035 | 59 | $0 (2024) |
| Mylan Specialty L.P. | $12,436 | 44 | $0 (2024) |
| Allergan, Inc. | $7,114 | 46 | $0 (2020) |
| Actelion Pharmaceuticals US, Inc. | $951.48 | 28 | $0 (2024) |
| Genentech USA, Inc. | $927.49 | 56 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $59,271 | 130 | GlaxoSmithKline, LLC. ($29,577) |
| 2023 | $89,212 | 124 | GlaxoSmithKline, LLC. ($63,360) |
| 2022 | $83,553 | 139 | GlaxoSmithKline, LLC. ($72,951) |
| 2021 | $32,970 | 79 | GlaxoSmithKline, LLC. ($21,301) |
| 2020 | $21,406 | 66 | GlaxoSmithKline, LLC. ($14,056) |
| 2019 | $34,996 | 145 | Boehringer Ingelheim Pharmaceuticals, Inc. ($19,858) |
| 2018 | $54,672 | 216 | Boehringer Ingelheim Pharmaceuticals, Inc. ($20,364) |
| 2017 | $57,159 | 207 | Sunovion Pharmaceuticals Inc. ($16,260) |
All Payment Transactions
1,106 individual payment records from CMS Open Payments — Page 1 of 45
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| Category: RESPIRATORY | ||||||
| 12/20/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,300.00 | General |
| Category: RESPIRATORY | ||||||
| 12/19/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Food and Beverage | In-kind items and services | $22.37 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 12/14/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $18.72 | General |
| Category: Respiratory | ||||||
| 12/12/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Travel and Lodging | Cash or cash equivalent | $28.14 | General |
| Category: RESPIRATORY | ||||||
| 12/10/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Food and Beverage | In-kind items and services | $121.83 | General |
| Category: RESPIRATORY | ||||||
| 12/09/2024 | ABBVIE INC. | TEFLARO (Drug), DALVANCE, AVYCAZ | Food and Beverage | In-kind items and services | $14.06 | General |
| Category: ANTI-INFECTIVE | ||||||
| 12/05/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $33.78 | General |
| Category: IMMUNOLOGY | ||||||
| 11/25/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $34.27 | General |
| Category: IMMUNOLOGY | ||||||
| 11/20/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Food and Beverage | In-kind items and services | $124.36 | General |
| Category: RESPIRATORY | ||||||
| 11/18/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,800.00 | General |
| Category: Respiratory | ||||||
| 11/15/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Education | In-kind items and services | $18.09 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/15/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Education | In-kind items and services | $18.09 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/13/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $119.76 | General |
| Category: Respiratory | ||||||
| 11/13/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Travel and Lodging | In-kind items and services | $78.34 | General |
| Category: Respiratory | ||||||
| 11/08/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Travel and Lodging | Cash or cash equivalent | $258.78 | General |
| Category: RESPIRATORY | ||||||
| 11/08/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Food and Beverage | Cash or cash equivalent | $56.30 | General |
| Category: RESPIRATORY | ||||||
| 11/06/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| Category: RESPIRATORY | ||||||
| 11/05/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Food and Beverage | In-kind items and services | $132.90 | General |
| Category: Cardiology | ||||||
| 11/05/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $14.89 | General |
| Category: Immunology | ||||||
| 10/30/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Education | In-kind items and services | $10.85 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/29/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,850.00 | General |
| Category: Respiratory | ||||||
| 10/29/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $30.40 | General |
| Category: IMMUNOLOGY | ||||||
| 10/22/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,800.00 | General |
| Category: Respiratory | ||||||
| 10/22/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $124.95 | General |
| Category: Respiratory | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 23 | 2,234 | 5,500 | $2.0M | $652,235 |
| 2022 | 20 | 2,089 | 5,422 | $2.0M | $616,778 |
| 2021 | 18 | 1,955 | 5,112 | $1.9M | $615,906 |
| 2020 | 23 | 2,085 | 7,129 | $2.5M | $794,094 |
Total Patients
8,363
Total Services
23,163
Medicare Billing
$2.7M
Procedure Codes
84
All Medicare Procedures & Services
84 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 562 | 2,640 | $747,120 | $262,778 | 35.2% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 361 | 1,167 | $697,866 | $206,290 | 29.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 355 | 531 | $213,794 | $77,446 | 36.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 249 | 338 | $102,076 | $34,845 | 34.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 149 | 156 | $85,488 | $22,491 | 26.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 43 | 43 | $24,424 | $7,650 | 31.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 26 | 75 | $14,625 | $4,972 | 34.0% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 42 | 42 | $7,704 | $4,623 | 60.0% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2023 | 71 | 72 | $9,980 | $3,665 | 36.7% |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 2023 | 37 | 62 | $8,060 | $2,840 | 35.2% |
| 94727 | Test to determine lung volumes using gas dilution or washout | Office | 2023 | 71 | 72 | $9,260 | $2,790 | 30.1% |
| 36556 | Insertion of non-tunneled central venous tube for infusion (5 years or older) | Facility | 2023 | 37 | 40 | $9,200 | $2,755 | 29.9% |
| 99496 | Transitional care management services for problem of high complexity | Office | 2023 | 11 | 11 | $7,150 | $2,655 | 37.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 20 | 20 | $9,060 | $2,611 | 28.8% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2023 | 71 | 72 | $17,840 | $2,453 | 13.8% |
| 99292 | Critical care, each additional 30 minutes | Facility | 2023 | 21 | 27 | $8,100 | $2,396 | 29.6% |
| 31645 | Aspiration of initial secretion of lung airway using an endoscope | Facility | 2023 | 18 | 20 | $8,100 | $2,306 | 28.5% |
| 99310 | Subsequent nursing facility care with high level of medical decision making, per day, if using time, at least 45 minutes | Facility | 2023 | 16 | 16 | $5,920 | $2,078 | 35.1% |
| 32555 | Aspiration of fluid from chest cavity using imaging guidance | Facility | 2023 | 20 | 22 | $6,732 | $1,984 | 29.5% |
| 31500 | Emergent insertion of breathing tube into windpipe using an endoscope | Facility | 2023 | 11 | 12 | $4,560 | $1,378 | 30.2% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 17 | 17 | $595.00 | $568.14 | 95.5% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 12 | 31 | $1,488 | $374.10 | 25.1% |
| 90688 | Influenza vaccine, quadrivalent, 0.5 ml dosage | Office | 2023 | 14 | 14 | $1,050 | $286.44 | 27.3% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 315 | 1,243 | $742,999 | $227,197 | 30.6% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 515 | 2,441 | $690,803 | $210,930 | 30.5% |
About Dr. Stephen Chen, MD
Dr. Stephen Chen, MD is a Internal Medicine healthcare provider based in Monterey Park, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/14/2005. The National Provider Identifier (NPI) number assigned to this provider is 1205821477.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Stephen Chen, MD has received a total of $433,239 in payments from pharmaceutical and medical device companies, with $59,271 received in 2024. These payments were reported across 1,106 transactions from 45 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($360,522).
As a Medicare-enrolled provider, Chen has provided services to 8,363 Medicare beneficiaries, totaling 23,163 services with total Medicare billing of $2.7M. Data is available for 4 years (2020–2023), covering 84 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Pulmonary Disease, Sleep Medicine
- Location Monterey Park, CA
- Active Since 09/14/2005
- Last Updated 04/20/2020
- Taxonomy Code 207R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1205821477
Products in Payments
- TRELEGY ELLIPTA (Drug) $74,752
- BREZTRI (Drug) $46,241
- AREXVY (Drug) $28,158
- Adempas (Drug) $25,019
- BEVESPI AEROSPHERE (Drug) $16,997
- UTIBRON (Drug) $16,218
- Yupelri (Drug) $12,259
- AVYCAZ (Drug) $6,806
- Creon (Drug) $6,540
- LOKELMA (Drug) $5,012
- NUCALA (Biological) $4,325
- LONHALA MAGNAIR (Drug) $3,323
- SYMBICORT (Drug) $2,045
- STIOLTO RESPIMAT (Drug) $1,558
- SPIRIVA (Drug) $1,327
- ANORO ELLIPTA (Drug) $1,301
- OFEV (Drug) $1,073
- Esbriet (Biological) $733.83
- DALVANCE (Drug) $627.89
- DUPIXENT (Biological) $624.50
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Monterey Park
Li Liu, M.d, M.D
Internal Medicine — Payments: $23,275
Internal Medicine $23,275
Mr. Thomas Tseng, Do, DO
Internal Medicine — Payments: $14,779
Internal Medicine $14,779
Dr. Robert Tzeng, Md, MD
Internal Medicine — Payments: $13,878
Internal Medicine $13,878
Dr. Jeffrey Chen, D.o, D.O
Internal Medicine — Payments: $13,049
Internal Medicine $13,049
Dr. Sunny Wong, D.o, D.O
Internal Medicine — Payments: $8,792
Internal Medicine $8,792
Wei Wang, Md, MD
Internal Medicine — Payments: $6,778
Internal Medicine $6,778